Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

NCT03474029 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT03474029
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03474029 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 2/3
Overall status
Recruiting
Start date
August 1, 2019
Completion date
December 31, 2029
Enrollment
3,400 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

latent tuberculosis